Cure Today: Antiangiogenic gene therapy

May 26, 2016

A novel antiangiogenic gene therapy, added to another antiangiogenic agent, Avastin (bevacizumab), led to significantly better overall survival (OS) in recurrent glioblastoma multiforme (GBM) compared with historical patients treated with Avastin alone, a small phase 2 trial showed. Read the full story at Cure Today


San Antonio Business Journal: Cancer money to boost local pediatric research

May 25, 2016

The Cancer Prevention & Research Institute of Texas has awarded nearly $11 million to the University of Texas Health Science Center at San Antonio in its latest funding round. That award includes $5 million to help establish the Texas Pediatric Patient-Derived Xenograft Facility. Read the full story at San Antonio Business Journal